Krystal Biotech (NASDAQ:KRYS) Reaches New 52-Week High – Still a Buy?

Krystal Biotech, Inc. (NASDAQ:KRYS) shares reached a new 52-week high on Wednesday . The company traded as high as $335.04 and last traded at $335.2510, with a volume of 51168 shares changing hands. The stock had previously closed at $323.37.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on KRYS shares. Weiss Ratings upgraded Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, April 9th. Jefferies Financial Group increased their price target on Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Citigroup increased their price target on Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Chardan Capital increased their price target on Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Finally, Guggenheim increased their price target on Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Ten research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Krystal Biotech has an average rating of “Moderate Buy” and a consensus target price of $329.78.

Krystal Biotech Stock Performance

The business has a fifty day simple moving average of $290.96 and a 200 day simple moving average of $269.76. The stock has a market capitalization of $10.21 billion, a price-to-earnings ratio of 46.34 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, May 4th. The company reported $1.83 EPS for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The firm had revenue of $116.36 million for the quarter, compared to analyst estimates of $112.11 million. On average, sell-side analysts forecast that Krystal Biotech, Inc. will post 7.83 earnings per share for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In other news, EVP John Charles Thomas sold 642 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total transaction of $193,903.26. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the sale, the insider directly owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 13.10% of the company’s stock.

Institutional Trading of Krystal Biotech

Large investors have recently modified their holdings of the stock. Western Wealth Management LLC acquired a new stake in shares of Krystal Biotech during the 1st quarter worth $34,000. Greenline Wealth Management LLC acquired a new stake in shares of Krystal Biotech during the 4th quarter worth $34,000. Sound Income Strategies LLC lifted its position in shares of Krystal Biotech by 1,270.0% during the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after buying an additional 127 shares during the last quarter. UMB Bank n.a. lifted its position in shares of Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after buying an additional 37 shares during the last quarter. Finally, Global Retirement Partners LLC lifted its position in shares of Krystal Biotech by 788.9% during the 4th quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock worth $39,000 after buying an additional 142 shares during the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.